Syntara Reports Parkinson’s Trial Signals as Pipeline Advances
SNT: $0.019 -2.63% · MC: $28M
Syntara reported preliminary Phase 2 results for SNT-4728 showing reduced inflammation in a Parkinson’s-related brain region, with additional post-quarter results indicating improved clinician-assessed motor signs versus placebo 12 weeks after treatment ended. Its AZALOX study advanced to the final Phase 1b dose cohort, while the SNT-9465 scar study expanded after quarter-end; top-line results are expected in early 2027. The company also received approximately $5 million in R&D tax incentives.

Comments